Vaccine-Induced Immunity Against Pertussis in Lung Transplant Candidates

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Given the high prevalence of Bordetella pertussis, patients with respiratory disorders are at risk of getting infected with this pathogen and developing pertussis. Therefore, they should be considered a target group for vaccination against this infection.

Aims — the objective of the study was to assess vaccine-induced immunity against pertussis in lung transplant candidates.

Methods. Twenty-four patients with severe bronchopulmonary diseases, aged 18 to 60, were vaccinated against pertussis with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine. Five patients underwent lung transplantation. Immunoglobulin G (IgG) antibodies (Abs) were measured using the RIDASCREEN® Bordetella IgG test system.

Results. In the post-vaccination period, only 8.3% of the patients developed such local reactions as tenderness and induration at the injection site. The proportions of patients who were seropositive for pertussis before vaccination, one month and one year after vaccination were 71, 100 and 100%, respectively (p = 0.02). A significant increase in anti-pertussis IgG Ab levels was identified one month after a single vaccine dose, and was still observed after 12 months. In the group of two-dose vaccination, there was no statistical difference between the levels of IgG Abs one month after the first dose and one month after the second dose. A significant increase in anti-Bordetella pertussis IgG Ab levels was observed in the group of initially seronegative patients compared to seropositive patients (p = 0.03). A year after vaccination, there was no statistically significant difference in IgG Ab levels between the patients with and without a history of lung transplantation.

Conclusions. The majority (71%) of patients with severe bronchopulmonary disease was seropositive for B. pertussis. Single-dose vaccination against pertussis was safe; it induced the production of additional specific Abs and an increase in their levels in all patients. Therapy administered after lung transplantation did not significantly affect the levels of vaccine-induced Abs.

Full Text

Restricted Access

About the authors

Mikhail P. Kostinov

I.I. Mechnikov Research Institute of Vaccines and Sera; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: monolit.96@mail.ru
ORCID iD: 0000-0002-1382-9403
SPIN-code: 5081-0740

MD, PhD, Professor, Corresponding Member of the RAS

Россия, Moscow; Moscow

Valentina B. Polishchuk

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: polischook@mail.ru
ORCID iD: 0000-0003-0533-0909
SPIN-code: 6294-9253

MD, PhD

Россия, Moscow

Alexey A. Ryzhov

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: 5231201@mail.ru
ORCID iD: 0000-0002-7759-2003
SPIN-code: 7238-8285

MD, PhD

Россия, Moscow

Kirill V. Mashilov

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: k.v.mashilov@gmail.com
ORCID iD: 0000-0003-1076-1930
SPIN-code: 5806-4450

MD, PhD, Associate Professor

Россия, Moscow

Natalia A. Karchevskaia

N.V. Sklifosovsky Research Institute for Emergency Medicine

Email: karchevskaia@mail.ru
ORCID iD: 0000-0001-8368-1056

Researcher

Россия, Moscow

Anna E. Vlasenko

Samara State Medical University

Author for correspondence.
Email: vlasenkoanna@inbox.ru
ORCID iD: 0000-0001-6454-4216

PhD in Engineering

Россия, Samara

References

  1. WHO position paper: pertussis vaccines. Wkly Epidemiol Rec. 2015;90:433–460. Available from: https://www.who.int/publications/i/item/WER9035
  2. Mbayei SA, Faulkner A, Miner C, et al. Severe Pertussis Infections in the United States, 2011–2015. Clin Infect Dis. 2019;69(2):218–226. doi: https://doi.org/10.1093/cid/ciy889
  3. Masseria C, Krishnarajah G. The estimated incidence of pertussis in people aged 50 years old in the United States, 2006–2010. BMC Infect Dis. 2015;15:534. doi: https://doi.org/10.1186/s12879-015-1269-1
  4. Jõgi P, Oona M, Toompere K, et al. Estimated and reported incidence of pertussis in Estonian adults: A seroepidemiological study. Vaccine. 2015;33(38):4756–4761. doi: https://doi.org/10.1016/j.vaccine.2015.08.007
  5. Chlibek R, Smetana J, Sosovickova R, et al. Seroepidemiology of whooping cough in the Czech Republic: estimates of incidence of infection in adults. Public Health. 2017;150:77–83. doi: https://doi.org/10.1016/j.puhe.2017.05.012
  6. Тюкавкина С.Ю., Харсеева Г.Г. Коклюш: эпидемиология, биологические свойства Bordetella pertussis, принципы лабораторной диагностики и специфической профилактики // Эпидемиология и инфекционные болезни. — 2014. — Т. 19. — № 4. — С. 50–59. [Tyukavkina SU, Kharseeva GG. Whooping cough: epidemiology, biological features of Bordetella Pertussis, laboratory diagnostics and specific prophylaxis. Epidemiologiya I infektsionnye bolezni. 2014;19(4):50–59. (In Russ.)]
  7. Миндлина А.Я., Полибин Р.В. О необходимости совершенствования тактики иммунопрофилактики коклюша // Пульмонология. — 2016. — Т. 26. — № 5. — С. 560–569. [Mindlina AYa, Polibin RV. About the need to improve immunization against the whooping cough. Pul’monologiya. 2016;26(5):560–569. (In Russ.)] doi: https://doi.org/10.18093/0869-0189-2016-26-5-560-569
  8. Галицкая М.Г., Намазова Л.С., Федосеенко М.В., и др. Реактогенность ацеллюлярной коклюшной вакцины и возможность ее использования у детей старшего возраста // Педиатрическая фармакология. — 2008. — Т. 5. — № 1. — С. 14–19. [Galitskaya MG, Namazova LS, Fedoseenko MV, et al. Reactogenicity of acellular pertussis vaccine and the possibility of its use in elder children. Pediatricheskaya farmakologiya. 2008;5(1):14–19. (In Russ.)]
  9. Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58–61. doi: https://doi.org/10.1097/01.inf.0000160914.59160.41
  10. Wearing HJ, Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog. 2009;5(10):e1000647. doi: https://doi.org/10.1371/journal.ppat.1000647
  11. Бабаченко И.В., Нестерова Ю.В., Скрипченко Н.В. Клинико-лабораторные особенности коклюша у детей разных возрастных групп // Педиатрия. Журнал им. Г.Н. Сперанского. — 2020. — Т. 99. — № 6. — С. 98–104. [Babachenko IV, Nesterova YV, Skripchenko NV. Clinical and laboratory peculiarities of whooping cough in children of different age groups. Pediatria n.a. G.N. Speransky. 2020;99(6):98–104. (In Russ.)] doi: https://doi.org/10.24110/0031-403X-2020-99-6-98-104
  12. Попова О.П., Мазанкова Л.Н., Скирда Т.А., и др. Клинико-диагностические особенности коклюша у детей старшего возраста // Российский вестник перинатологии и педиатрии. — 2019. — Т. 64. — № 4. — С. 70–75. [Popova OP, Mazankova LN, Skirda TA, et al. Clinical and diagnostic features of pertussis in older children. Rossiyskiy Vestnik Perinatologii i Pediatrii. (Russian Bulletin of Perinatology and Pediatrics). 2019;64(4):70–75. (In Russ.)] doi: https://doi.org/10.21508/1027-4065-2019-64-4-70-75
  13. Nunes A, Abreu A, Furtado B, et al. Epidemiology of pertussis among adolescents, adults, and older adults in selected countries of Latin American: a systematic review. Hum Vaccin Immunother. 2021;17(6):1733–1746. doi: https://doi.org/10.1080/21645515.2020.1827613
  14. Chen CC, Balderston McGuiness C, Krishnarajah G, et al. Estimated incidence of pertussis in people aged < 50 years in the United States. Hum Vaccin Immunother. 2016;12(10):2536–2545. doi: https://doi.org/10.1080/21645515.2016.1186313
  15. European Centre for Disease Prevention and Control. 2022. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=3&SelectedCountryIdBy Disease=-1
  16. Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1–44. doi: https://doi.org/10.15585/mmwr.rr6702a1
  17. Jenkins VA, Savic M, Kandeil W. Pertussis in high-risk groups: an overview of the past quarter-century. Hum Vaccin Immunother. 2020;16(11):2609–2617. doi: https://doi.org/10.1080/21645515.2020.1738168
  18. Capili CR, Hettinger A, Rigelman-Hedberg N, et al. Increased risk of pertussis in patients with asthma. J Allergy Clin Immunol. 2012;129(4):957–963. doi: https://doi.org/10.1016/j.jaci.2011.11.020
  19. Грачева Н.М., Девяткин А.В., Петрова М.С., и др. Коклюш (клиника, диагностика, лечение) // Поликлиника. — 2016. — № 2-1. — С. 13–25. [Gracheva NM, Devjatkin AV, Petrova MS, et al. Kokljush (klinika, diagnostika, lechenie). Poliklinika 2016;(2- 1):13–25. (In Russ.)]
  20. Scanlon K, Skerry C, Carbonetti N. Association of Pertussis Toxin with Severe Pertussis Disease. Toxins (Basel). 2019;11(7):373. doi: https://doi.org/.3390/toxins11070373
  21. Taranger J, Trollfors B, Lagergård T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis. 2000;181(3):1010–1013. doi: https://doi.org/10.1086/315318
  22. Sheridan SL, Frith K, Snelling TL, et al. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Rev Vaccines. 2014;13(9):1081–1106. doi: https://doi.org/10.1586/14760584.2014.944167
  23. Prelog M, Almanzar G, Rieber N, et al. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination. Vaccine. 2013;31(2):387–393. doi: https://doi.org/10.1016/j.vaccine.2012.10.105
  24. Plotkin SA. Updates on immunologic correlates of vaccine-induced protection. Vaccine. 2020;38(9):2250–2257. doi: https://doi.org/10.1016/j.vaccine.2019.10.046
  25. Keitel WA, Muenz LR, Decker MD, et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999;180(2):397–403. doi: https://doi.org/10.1086/314869
  26. Boey L, Bosmans E, Ferreira LB, et al. Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients. Vaccines. 2021;9(1):18. doi: https://doi.org/10.3390/vaccines9010018
  27. Wilkinson TMA, Van den Steen P, Cheuvart B, et al. Seroprevalence of Bordetella pertussis Infection in Patients with Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort. COPD. 2021;18(3):341–348. doi: https://doi.org/10.1080/15412555.2021.1920904
  28. Kostinov MP, Latysheva EA, Kostinova AM, et al. Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency. Vaccines (Basel). 2020;8(4):640. doi: https://doi.org/10.3390/vaccines8040640
  29. Versteegen P, Valente Pinto M, Barkoff AM, et al. Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom. EBioMedicine. 2021;65:103247. doi: https://doi.org/10.1016/j.ebiom.2021.103247
  30. Duchini A, Goss JA, Karpen S, et al. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003;16(3):357–364. doi: https://doi.org/10.1128/CMR.16.3.357-364
  31. Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11(10):2020–2030. doi: https://doi.org/10.1111/j.1600-6143.2011.03753.x
  32. Manothummetha K, Chuleerarux N, Sanguankeo A, et al. Immunogenicity and Risk Factors Associated with Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2022;5(4):e226822. doi: https://doi.org/.1001/jamanetworkopen.2022.6822

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Concentration of IgG AT to Bordetella pertussis at each control point, individual values, geometric mean concentration and 95% confidence interval are shown

Download (70KB)
Indexing metadata
3. Fig. 2. Concentration of IgG antibodies to Bordetella pertussis depending on the vaccination schedule at each control point, individual values, geometric mean concentration and 95% confidence interval are shown

Download (91KB)
Indexing metadata
4. Fig. 3. Concentration of IgG antibodies to Bordetella pertussis depending on the initial level of antibodies, individual values, geometric mean concentration and 95% confidence interval are shown

Download (91KB)
Indexing metadata
5. Fig. 4. The intensity of change in the level of IgG antibodies to Bordetella pertussis depending on the initial level 1 month after vaccination relative to the initial level, individual values, median, interquartile range, minimum and maximum values ​​are shown

Download (85KB)
Indexing metadata
6. Fig. 5. Concentration of IgG antibodies to Bordetella pertussis depending on the type of lung transplantation, individual values, geometric mean concentration and 95% confidence interval are shown

Download (99KB)
Indexing metadata

Copyright (c) 2024 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies